QIAamp 96 Virus QIAcube HT Kit

For automated high-throughput purification of viral RNA and DNA from a variety of samples

Features

  • Simple and reliable automated processing for cost and time savings
  • Suitable for many samples, including blood, tissues, swabs and body fluids
  • Consistent, high yields
  • Efficient removal of inhibitors and contaminants
  • Purified nucleic acids ready for analysis by real-time PCR or RT-PCR
QIAamp 96 Virus QIAcube HT Kit (5)

Cat. No. / ID: 57731

For 480 preps: QIAamp 96 plates, QIAGEN Proteinase K, carrier RNA, buffers
KitAccessories
QIAamp 96 Virus QIAcube HT Kit
QIAcube HT Plasticware
The QIAamp 96 Virus QIAcube HT Kit is intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.

Product Details

The QIAamp 96 Virus QIAcube HT Kit enables simple, automated purification of viral RNA and DNA on the QIAcube HT system. Using proven QIAamp silica-membrane technology in a convenient 96-well format, contaminants and inhibitors are removed to yield high-quality nucleic acids that are ready for downstream analysis.

Performance

The QIAamp 96 Virus QIAcube HT Kit enables automated purification of viral RNA and DNA from a broad range of sample types including fresh or frozen tissues, blood and other body fluids. The procedure yields high-quality viral nucleic acids that perform well in downstream PCR and RT-PCR analyses (see figure  Reliable purification from a range of sample types).

QIAcube HT with the dedicated QIAamp 96 Virus QIAcube HT Kit lets users increase sample purification throughput without having to compromise on quality or reliability. The procedure provides high yields of pure RNA or DNA that perform well in downstream analyses, similar to other QIAGEN DNA purification solutions (see figures  Reliable automated purification and  High sensitivity of viral nucleic acids in PCR and RT-PCR).

See figures

Principle

The QIAamp 96 Virus QIAcube HT Kit combines the selective binding properties of a silica-based membrane with a high-throughput 96-well format, and is designed for fully automated, simultaneous processing of 24–96 samples on the QIAcube HT instrument.
 
Kit specifications
Specification Description
Number of samples 24–96 samples (to be processed in increments of 8)
Sample input volume Blood and other body fluids: up to 200 μl (for sample volumes less than 200 μl, add PBS) 
Tissues: up to 20 mg tissue
Elution volume 100 μl
Duration 96 samples in approximately 145 minutes
24 samples in approximately 90 minutes

Procedure

The QIAamp 96 Virus QIAcube HT procedure is fast and simple with the QIAcube HT instrument. Samples are lysed under highly denaturing conditions at room temperature in the presence of QIAGEN proteinase K and Buffer ACL, which together ensure the inactivation of nucleases. Adding Buffer ACB adjusts the binding conditions for the co-purification of DNA and RNA. The lysate is then transferred to a QIAamp 96 plate. During vacuum, nucleic acids are adsorbed onto the silica membranes while contaminants pass through. Three efficient wash steps remove the remaining contaminants and enzyme inhibitors, and nucleic acids are eluted in Buffer AVE. Some samples may require a pretreatment.

Applications

The high-quality nucleic acids are ready to use in all downstream applications, including sensitive detection assays using quantitative, real-time PCR or RT-PCR.

Supporting data and figures

Resources

Quick-Start Protocols (3)
For use with QIAcube HT Prep Manager Software; not compatible with QIAcube HT Operating Software 4.17
For use with QIAcube HT Operating Software 4.17; not for use with QIAcube HT Prep Manager Software
For use with QIAcube HT Operating Software 4.17; not for use with QIAcube HT Prep Manager Software
Protocol Files (2)
Installation file (.msi) for installing the Q Protocol run file (.qsp) in the QIAcube HT software. For use with QIAcube HT Operating Software 4.17; not for use with QIAcube HT Prep Manager Software.
Q Protocol notes for purification of viral nucleic acids from human samples on the QIAcube HT using the QIAamp 96 Virus QIAcube HT Kit; use with the QIAamp 96 Virus QIAcube HT V1.qsp run file. For use with QIAcube HT Operating Software 4.17; not for use with QIAcube HT Prep Manager Software.
Kit Handbooks (2)
For use with QIAcube HT Prep Manager Software; not compatible with QIAcube HT Operating Software 4.17
For use with QIAcube HT Operating Software 4.17; not compatible with QIAcube HT Prep Manager Software
Instrument User Manuals (2)
Instrument user manual for automated mid- to high-throughput nucleic acid purification in 96-well format using silica membrane technology; for use with QIAcube HT Prep Manager Software v1.1.1.
Instrument user manual for automated mid- to high-throughput nucleic acid purification in 96-well format using silica membrane technology; for use with QIAcube HT Operating Software 4.17; not for use with QIAcube HT Prep Manager Software
Brochures & Guides (1)
For fast and reliable automated 96-well nucleic acid purification

FAQ

Are there important considerations for plasma generation and urine handling?

It is strongly advised to follow the recommendations for preparing sample material provided in the corresponding Protocol Sheet to ensure reliable results.

Plasma: It is recommended to perform plasma separation immediately after blood collection when using EDTA or citrate as anticoagulant to prevent the release of genomic DNA into the plasma fraction.

Urine: Because circulating cell-free DNA in non-stabilized urine samples is rapidly degraded after sample collection due to high nuclease activity, eluates may contain no DNA or exhibit low DNA concentration. Therefore, it is recommended to stabilize urine samples. Even when using stabilized urine, it is recommended to perform a centrifugation step immediately after stabilization to prevent the release of genomic DNA from cells. Alternatively, non-stabilized urine samples can be processed immediately after collection and centrifugation using ATL-pretreatment and automated DNA extraction as described in the corresponding Protocol Sheet.

FAQ ID - 3699